Scarica l'app Stockscreener
40.30
0.15%
-0.06
Dopo l'orario di chiusura:
40.15
-0.15
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$40.36
Aprire:
$40.1
Volume 24 ore:
2.02M
Relative Volume:
0.44
Capitalizzazione di mercato:
$82.01B
Reddito:
$40.95B
Utile/perdita netta:
$5.16B
Rapporto P/E:
18.56
EPS:
2.1708
Flusso di cassa netto:
$5.47B
1 W Prestazione:
-2.84%
1M Prestazione:
+3.15%
6M Prestazione:
-0.22%
1 anno Prestazione:
-5.02%
Intervallo 1D:
$40.05
$40.36
Intervallo di 1 settimana:
$40.02
$41.39
Portata 52W:
$31.71
$42.63
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GSK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
40.30 | 81.24B | 40.95B | 5.16B | 5.47B | 2.1708 |
|
LLY
Lilly Eli Co
|
762.93 | 681.42B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.16 | 426.76B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
221.99 | 390.07B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.29 | 237.08B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
NVO
Novo Nordisk Adr
|
61.85 | 258.61B | 45.44B | 16.18B | 9.21B | 3.634 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
GSK PLC Sponsored ADR $GSK Shares Sold by Douglas Lane & Associates LLC - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Bard Financial Services Inc. Grows Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Shares - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Acquired by First Hawaiian Bank - MarketBeat
GSK (NYSE:GSK) Stock Unloaded Rep. Robert B. Aderholt - MarketBeat
GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years - Benzinga
First Bank & Trust Makes New $1.22 Million Investment in GSK PLC Sponsored ADR $GSK - MarketBeat
Geneos Wealth Management Inc. Boosts Stock Holdings in GSK PLC Sponsored ADR $GSK - Defense World
Chelsea Counsel Co. Reduces Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Acadian Asset Management LLC Boosts Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Purchased by NewEdge Advisors LLC - MarketBeat
Fred Alger Management LLC Boosts Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):